

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)*

VOLUNTARY ANNOUNCEMENT

PROPOSED INCLUSION OF ASANDEUTERTINIB (TY-9591) IN PRIORITY REVIEW; AND UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company’s investigational Class 1 new drug, Asandeutertinib (TY-9591), has been proposed to be included in the List of Products for Priority Review (優先審評品種名單) by the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration (the “**NMPA**”), with the proposed indication being: first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), central nervous system (CNS) metastases harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutation.

The Board has also noted the recent unusual fluctuations in the price and trading volume of the shares of the Company. Having made reasonable enquiries, the Board confirms that, as of the time of this announcement, save for those disclosed above, it is not aware of any reasons for such fluctuations, or any information that needs to be disclosed to avoid a false market in the Company’s securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As of the date of this announcement, the Board confirms that the Group’s business operations remain normal and stable, with its core business progressing smoothly, and there are no material matters requiring disclosure that have come to the attention of the Board and the Company’s management.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that the relevant product will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

TYK Medicines, Inc

(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 7 January, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.